Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

Johnson & Johnson's experimental drug JNJ-6143 showed promising results in a Phase 1 study, with 77% of patients achieving a 50% or greater reduction in PSA levels. The drug targets prostate cancer cells through a novel mechanism. The 50-mg dose will advance to further clinical development, including a Phase 2 study. The company highlights the significant unmet needs in advanced prostate cancer treatment.

Johnson & Johnson's experimental prostate cancer drug JNJ-6143 showed promising results in an early trial, with 77% of patients experiencing a PSA decline of at least 50%. The drug uses a novel approach called RIPTAC, targeting cancer cells' proteins. The findings were presented at the 2026 ESMO Congress, but further trials are needed to confirm safety and effectiveness.

Johnson & Johnson reported positive results for its investigational drug JNJ-6143 in a Phase 1 prostate cancer trial, with 77% of patients showing a confirmed PSA decline. The company selected a 50-mg daily dose for Phase 2 testing. The drug is designed to target the androgen receptor and BRD4 protein. Johnson & Johnson acquired Halda Therapeutics, the drug's original developer, for $3.05 billion in 2025.

Johnson & Johnson reported a phase 3 study showing apalutamide plus hormone therapy before and after surgery reduced recurrence-related events or death in high-risk prostate cancer. The study involved 408 patients, with a 62% reduction in hazard for the treatment group. The company noted the regimen is not yet approved for this use.

Johnson & Johnson reported Phase 3 PROTEUS substudy results showing apalutamide plus ADT significantly improved event-free survival in high-risk prostate cancer patients compared to surgery alone, reducing recurrence or death risk by 62%. The treatment also showed improvements in secondary and exploratory endpoints. The safety profile was consistent with prior studies. Apalutamide is currently approved for advanced prostate cancer but not for this specific use.

Johnson & Johnson's drug JNJ-6143, acquired via its $3B Halda takeover, showed promise in early-stage prostate cancer trials. 77% of patients saw PSA levels drop by 50%+, with a favorable safety profile. J&J is now running a phase 2 trial. According to the lead investigator, the drug is 'highly active' in mCRPC patients.